



PATENT
ATTORNEY DOCKET NO. JHU1300-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sidransky and Baylin Art Unit: 1656
Serial No.: 09/225,904 Examiner: S. Houtteman
Filed: January 5, 1999
Title: METHOD OF DETECTION OF NEOPLASTIC CELLS

Commissioner for Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR § 1.821(f)

Sir:

I, RICHARD J. IMBRA, declare that I was involved in the preparation of the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: _____

RICHARD J. IMBRA
Registration No. 37,643

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, **November 22, 2000**, in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

Encl: Jankovs Yucam

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

COPY

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7.

Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

Patent Software: (703) 308-1123

Please return a copy of this notice with your response.



Grp 1656 H
Box 504

PATENT
Attorney Docket No.: JHU1300-4

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sidransky and Baylin Art Unit: 1656
Application No.: 09/225,904 Examiner: S. Houtteman
Filed: January 5, 1999
Title: METHOD OF DETECTION OF NEOPLASTIC CELLS

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL SHEET

RECEIVED

DEC 21 2000

Dear Sir:

TECH CENTER 1600/2900

Transmitted herewith for the above-unidentified application please find:

1. Response to the Office Action mailed June 22, 2000;
2. Exhibit A;
3. Petition for 2 month Extension of Time;
4. Check in the amount of \$195.00;
5. Copy of Notice to Comply;
6. Statement Under 37 C.F.R. §§ 1.821 (f) and (g);
7. Verified Statement Under 37 C.F.R. §§ 1.821 (f);
8. Disk w/paper copy of Sequence Listing
9. Return Postcard

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, **November 22, 2000**, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Linda Jonkers-Yocom
Name of Person Mailing Paper

Signature


The Fee for this Response is calculated as follows:

For	Claims Remaining After Amendment	Highest Number Previously Paid For	Extra Claims	Large Entity Rate	Small Entity Rate	Calculations
Total Claims	11	20	16	x \$18.00	x \$9.00	\$.00
Independent Claims	2	3	0	x \$78.00	x \$39.00	\$.00
Multiple Claims				\$260.00	\$130.00	\$.00
					TOTAL FEE	\$.00

Enclosed is a check in the TOTAL amount of \$195.00 for the one-month extension of time. The Commissioner is hereby authorized to charge any additional fees associated with the filing submitted herewith, or credit any overpayments to Deposit Account No. 50-1355. A copy of this Transmittal Sheet is enclosed.

Respectfully submitted,

Date: 11/22/00



Lisa A. Haile, Ph.D.
Reg. No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189